Related Experiment Video
Updated: Sep 1, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PARP1 inhibition elicits immune responses against non-small cell lung cancer
Pan Juncheng1,2,3, Antoine Lafarge1,2,3, Guido Kroemer1,2,4
1Equipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Abstract:
High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
DNA Damage can Stall the Cell Cycle